New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) announced new AI-enabled features ...

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Russian carrier Ural Airlines is embarking on a programme to extend the operational life of Airbus A320-family jets – claiming a first for the country. Ural Airlines operates an all-Airbus ...

Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

Dexcom (Nasdaq:DXCM) announced that it appointed Rick Osterloh to its board of directors, effective Feb. 26, 2026.

Leach succeeds Abbott EVP of Diabetes Care, Chris Scoggins, in the position. Eric Benjamin, Insulet’s EVP and COO, will serve as the vice chair for the medical device industry association’s Diabetes ...